Drug Profile
Ranibizumab biosimilar - Coherus BioSciences
Alternative Names: CHS-3351; CIMERLI; LUCENTISLatest Information Update: 21 Nov 2021
Price :
$50
*
At a glance
- Originator Coherus Biosciences
- Developer Coherus BioSciences
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Eye disorders